|Tel||+44 (0)1865 74171|
|Fax||+44 (0)1865 793101|
Clinical Lead Thames Valley DeNDRoN
- Consultant Psychiatrist
I am interested in dementia and in treatment resistant depression. I lead the Thames Valley DeNDRoN local research network, which supports a wide variety of studies in dementia and neurological disease, has an excellent track record of recruitment and study delivery, and is focused on innovative strategies to integrate research and clinical practice. I am the Coordinating Editor of the Cochrane Dementia and Cognitive Improvement Group and lead an NIHR programme on reviews of diagnostic test accuracy in dementia. We are leading an international initiative to improve standards of reporting of diagnostic studies. I am interested in the problem of people with dementia who get lost and have created a new, volunteer-based service to mitigate its impact: Neighbourhood Return.
The possibility that ketamine infusions could be given in routine NHS ECT suites to patients with treatment resistant depression is the focus of an NIHR funded study which I lead. We are also collaborating with colleagues from Department of Primary Care Health Sciences to explore the range of experiences of people receiving ECT and to create a ‘Healthtalkonline’ module for ECT.
Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia.
Noel-Storr AH. et al, (2013), Alzheimers Dement, 9, e96 - e105
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R. et al, (2012), N Engl J Med, 366, 893 - 903
Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review.
Farrimond LE. et al, (2012), Bmj Open, 2
Metal protein attenuating compounds for the treatment of Alzheimer's dementia
Sampson EL. et al, (2012), Cochrane Database of Systematic Reviews
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M. et al, (2012), Cochrane Database Syst Rev, 3